Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC12837 Compound 56 A potent EGFR inhibitor Compound 56 Chemical Structure
  3. GC46123 Comprehensive Kinase Screening Library For screening of a variety of kinase inhibitors Comprehensive Kinase Screening Library Chemical Structure
  4. GC35728 Conteltinib

    CT-707

     Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM. Conteltinib Chemical Structure
  5. GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF CP-547632 Chemical Structure
  6. GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy. CP-547632 hydrochloride Chemical Structure
  7. GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. CP-547632 TFA Chemical Structure
  8. GC12980 CP-673451 PDGFRα/β inhibitor,potent and selective CP-673451 Chemical Structure
  9. GC13091 CP-724714 HER2 inhibitor,potent and selective CP-724714 Chemical Structure
  10. GC62274 CPL304110 CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively. CPL304110 Chemical Structure
  11. GC14906 Crenolanib (CP-868596)

    CP-868596;CP 868596;CP868596

     Crenolanib (CP-868596) is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively. Crenolanib (CP-868596) Chemical Structure
  12. GC12616 Crizotinib hydrochloride

    inhibitor of the c-Met kinase and the NPM-ALK

     Crizotinib hydrochloride Chemical Structure
  13. GC38412 Crotonoside

    2-Hydroxyadenosine, Isoguanine riboside, Isoguanosine, NSC 12161

     A guanosine analog with diverse biological activities Crotonoside Chemical Structure
  14. GC25313 CS-2660 (JNJ-38158471) CS-2660 (JNJ-38158471) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50 of 40 nM. CS-2660 (JNJ-38158471) also inhibits closely related tyrosine kinases such as RET (c-RET) and Kit (c-Kit) with IC50 of 180 nM and 500 nM，while it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. CS-2660 (JNJ-38158471) Chemical Structure
  15. GC33241 CSF1R-IN-1 CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM. CSF1R-IN-1 Chemical Structure
  16. GC64961 CSF1R-IN-2

    CSF1R-IN-2, CSF1R Inhibitor 2, Elzovantinib

     CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively. CSF1R-IN-2 Chemical Structure
  17. GC64805 CSF1R-IN-3 CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity. CSF1R-IN-3 Chemical Structure
  18. GC35753 CT-721 CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. CT-721 Chemical Structure
  19. GC67774 CT52923 CT52923 Chemical Structure
  20. GC50076 CTA 056 ITK inhibitor CTA 056 Chemical Structure
  21. GC17637 CTX0294885 Pan-kinase inhibitor CTX0294885 Chemical Structure
  22. GC16008 CUDC-101 A multi-target inhibitor of HDACs, EGFR, and HER2 CUDC-101 Chemical Structure
  23. GC38180 Cyasterone Cyasterone Chemical Structure
  24. GC13780 Cyclotraxin B TrkB receptor antagonist Cyclotraxin B Chemical Structure
  25. GC16731 CZC 54252 hydrochloride CZC 54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC 54252 hydrochloride Chemical Structure
  26. GC16038 CZC-25146 LRRK2 inhibitor CZC-25146 Chemical Structure
  27. GC35792 CZC-25146 hydrochloride CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride Chemical Structure
  28. GC33351 CZC-8004 (CZC-00008004)

    Dianilinopyrimidine-01

     CZC-8004 (CZC-00008004) (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 (CZC-00008004) can bind a range of tyrosine kinases, including EGFR and VEGFR2 with IC50 values of 650 and 437 nM, respectively. CZC-8004 (CZC-00008004) Chemical Structure
  29. GC43433 D-Glucosamine-6-sulfate

    GlcN-6S

     D-Glucosamine-6-sulfate is a naturally occurring glycosaminoglycan. D-Glucosamine-6-sulfate Chemical Structure
  30. GC62712 DA-JC4 DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways. DA-JC4 Chemical Structure
  31. GC10225 Dacomitinib (PF299804, PF299)

    PF-00299804; PF-299804; PF 299804; PF 00299804

     Dacomitinib (PF299804, PF299) (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively. Dacomitinib (PF299804, PF299) Chemical Structure
  32. GC15211 Damnacanthal p56lck tyrosine kinase inhibitor Damnacanthal Chemical Structure
  33. GC15217 Danusertib (PHA-739358)

    PHA-739358

     A pan-Aurora kinase and Abl inhibitor Danusertib (PHA-739358) Chemical Structure
  34. GN10336 Daphnetin

    7,8-Dihydroxycoumarin, NSC 633563

     Daphnetin Chemical Structure
  35. GC15568 Dasatinib (BMS-354825)

    BMS 354825, Sprycel

     An inhibitor of Abl and Src Dasatinib (BMS-354825) Chemical Structure
  36. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor Dasatinib hydrochloride Chemical Structure
  37. GC15884 Dasatinib Monohydrate Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. Dasatinib Monohydrate Chemical Structure
  38. GC45687 Dasatinib N-oxide A major metabolite of dasatinib Dasatinib N-oxide Chemical Structure
  39. GC62569 DBPR112 DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy. DBPR112 Chemical Structure
  40. GC14007 DCC-2036 (Rebastinib)

    DCC-2036

     DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib) Chemical Structure
  41. GC11171 DCC-2618

    DCC2618;DCC 2618

     A dual inhibitor of c-Kit and c-MET DCC-2618 Chemical Structure
  42. GC33361 DDR Inhibitor DDR Inhibitor is a potent discoidin domain receptor (DDR) inhibitor, with an IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM. DDR Inhibitor Chemical Structure
  43. GC17365 DDR1-IN-1 selective DDR1 receptor tyrosine kinase inhibitor DDR1-IN-1 Chemical Structure
  44. GC35822 DDR1-IN-1 dihydrochloride DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM). DDR1-IN-1 dihydrochloride Chemical Structure
  45. GC31724 DDR1-IN-2

    7rh

     DDR1-IN-2 (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1), with an IC50 of 13.1 nM, and also less potently inhibits DDR2, with an IC50 of 203 nM. DDR1-IN-2 Chemical Structure
  46. GC33297 DDR1-IN-3 DDR1-IN-3 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR1-IN-3 also inhibits TRK family. DDR1-IN-3 Chemical Structure
  47. GC64268 DDR1-IN-4 DDR1-IN-4 (Compound 2.45) is a selective and potent Discoidin Domain Receptor 1 (DDR1) autophosphorylation inhibitor, with IC50 values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively. DDR1-IN-4 Chemical Structure
  48. GC65378 DDR1-IN-5 DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 4.1 nM. DDR1-IN-5 has anti-cancer activity. DDR1-IN-5 Chemical Structure
  49. GC66476 DDR1-IN-6 DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 9.7 nM. DDR1-IN-6 has anti-cancer activity. DDR1-IN-6 Chemical Structure
  50. GC70345 DDR2-IN-1 DDR2-IN-1 is potent DDR2 inhibitor with an IC50 of 26 nM. DDR2-IN-1 Chemical Structure
  51. GC16813 Defactinib

    PF-04554878, VS-6063

    FAK phosphorylation inhibitor

     Defactinib Chemical Structure
  52. GC35827 Defactinib hydrochloride

    VS-6063 hydrochloride; PF 04554878 hydrochloride

     A novel FAK inhibitor Defactinib hydrochloride Chemical Structure
  53. GC47182 Dehydrolithocholic Acid

    3-keto LCA, 3-keto Lithocholate, 3-keto Lithocholic Acid, 3-KLCA, 3-oxo LCA, 3-oxo Lithocholate, 3-oxo Lithocholic Acid

     Dehydrolithocholic Acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM). Dehydrolithocholic Acid Chemical Structure
  54. GC14905 Demethylasterriquinone B1

    DMAQ B1,L-783,281

    An insulin receptor (IR) activator

     Demethylasterriquinone B1 Chemical Structure
  55. GC19399 Derazantinib

    ARQ 087

     Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively. Derazantinib Chemical Structure
  56. GC62107 DGY-06-116 DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM. DGY-06-116 Chemical Structure
  57. GC30768 Dihexa (PNB-0408) Dihexa (PNB-0408) (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is an oral active, blood-brain barrier-permeable angiotensin IV analogue. Dihexa (PNB-0408) Chemical Structure
  58. GC68986 Disitamab

    RC48-0

    Disitamab (RC48-0) is a humanized monoclonal antibody that targets HER2. Disitamab can be used to synthesize antibody-drug conjugates (ADCs), such as Disitamab vedotin.

     Disitamab Chemical Structure
  59. GC64039 Disitamab vedotin Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. Disitamab vedotin Chemical Structure
  60. GC14298 DMH-1

    BMP Inhibitor II, DorsoMorphin Homolog 1, VU036482

     Selective BMP ALK2 receptor DMH-1 Chemical Structure
  61. GC17098 DMH4 VEGFR-2 inhibitor DMH4 Chemical Structure
  62. GC43503 DMHAPC-Chol

    Dimethyl Hydroxyethyl Aminopropane Carbamoyl Cholesterol Iodide

     DMHAPC-Chol is a cationic cholesterol. DMHAPC-Chol Chemical Structure
  63. GC17024 DMPQ dihydrochloride PDGFRβ inhibitor DMPQ dihydrochloride Chemical Structure
  64. GC69000 Dosimertinib-d5 mesylate

    Dosimertinib-d5 (mesylate) is an effective orally active EGFR inhibitor. It reduces the expression of p-EGFR and p-ERK proteins. Dosimertinib-d5 (mesylate) exhibits anti-proliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has potential for research in non-small cell lung cancer (NSCLC).

     Dosimertinib-d5 mesylate Chemical Structure
  65. GC13547 Dovitinib (TKI-258, CHIR-258)

    CHIR258, TKI-258

     Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity. Dovitinib (TKI-258, CHIR-258) Chemical Structure
  66. GC10165 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib (TKI258) Lactate Chemical Structure
  67. GC11372 Dovitinib Dilactic acid FLT3 inhibitor Dovitinib Dilactic acid Chemical Structure
  68. GC32760 Dovitinib lactate (CHIR-258 lactate) Dovitinib lactate (CHIR-258 lactate) (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib lactate (CHIR-258 lactate) Chemical Structure
  69. GC45767 Dovitinib-d8 An internal standard for the quantification of dovitinib Dovitinib-d8 Chemical Structure
  70. GC35897 DPH A potent cell permeable c-Abl activator DPH Chemical Structure
  71. GC62597 DS-1205b free base DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo. DS-1205b free base Chemical Structure
  72. GC72453 Duligotuzumab Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3). Duligotuzumab Chemical Structure
  73. GC72454 Dusigitumab Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1. Dusigitumab Chemical Structure
  74. GC62946 DYRK1-IN-1 DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor. DYRK1-IN-1 Chemical Structure
  75. GC70985 Dyrk1A-IN-3 Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A)inhibitor, maintains high levels of DYRK1A binding affinity (IC50=76 nM). Dyrk1A-IN-3 Chemical Structure
  76. GC69031 Dyrk1A-IN-5

    Dyrk1A-IN-5 (compound 5j) is a potent and selective inhibitor of DYRK1A with an IC50 value of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC50 of 0.5 μM. Dyrk1A-IN-5 inhibits the phosphorylation of tau protein at Thr212, with an IC50 of 2.1 μM. Dyrk1A-IN-5 can be used for research on Down syndrome.

     Dyrk1A-IN-5 Chemical Structure
  77. GC62947 DYRKs-IN-1 hydrochloride DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity. DYRKs-IN-1 hydrochloride Chemical Structure
  78. GC12149 E-3810 E-3810 Chemical Structure
  79. GC69037 E7090

    E7090 is an effective selective FGFR inhibitor with oral activity, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4 respectively.

     E7090 Chemical Structure
  80. GC62696 E7090 succinate E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively. E7090 succinate Chemical Structure
  81. GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. EAI001 Chemical Structure
  82. GC12281 EAI045 Inhibitor of L858R/T790M EGFR mutants EAI045 Chemical Structure
  83. GC64730 EB-42486 EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM). EB-42486 Chemical Structure
  84. GC32825 eCF506 An inhibitor of Src kinases eCF506 Chemical Structure
  85. GC67879 Edecesertib

    GS-5718

     Edecesertib Chemical Structure
  86. GC19418 Edicotinib

    JNJ-40346527; JNJ-527

     Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease. Edicotinib Chemical Structure
  87. GC72468 Efruxifermin Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin Chemical Structure
  88. GC16183 EG00229

    Nrp1 inhibitor

     EG00229 Chemical Structure
  89. GC16321 EGF816 EGF816 (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively. EGF816 Chemical Structure
  90. GC11312 EGFR Inhibitor

    Epidermal Growth Factor Receptor Inhibitor

     EGFR Inhibitor is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR Inhibitor also inhibits mutant EGFRL858R and EGFRL861Q with IC50s of 63 nM and 4 nM, respectively. EGFR Inhibitor displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR Inhibitor induces cells apoptosis and has antitumor activity. EGFR Inhibitor Chemical Structure
  91. GC35965 EGFR mutant-IN-1 EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFRL858R/T790M/C797S mutant inhibitor with an IC50 of 27.5 nM, while being a significantly less potent for EGFRWT (IC50 >1.0 μM). EGFR mutant-IN-1 Chemical Structure
  92. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate Chemical Structure
  93. GC62562 EGFR-IN-11 EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC50 of 18 nM for triple mutant EGFRL858R/T790M/C797S. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1. EGFR-IN-11 Chemical Structure
  94. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17 Chemical Structure
  95. GC33195 EGFR-IN-2 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. EGFR-IN-2 Chemical Structure
  96. GC19132 EGFR-IN-3 EGFR-IN-3 is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. EGFR-IN-3 has the potential for NSCLC research. EGFR-IN-3 Chemical Structure
  97. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5 Chemical Structure
  98. GC68440 EGFR-IN-69 EGFR-IN-69 Chemical Structure
  99. GC35966 EGFR-IN-7 EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 shows anti-tumor activity. EGFR-IN-7 can be used for the research of various cancers. EGFR-IN-7 Chemical Structure
  100. GC69043 EGFR-IN-70

    EGFR-IN-70 (compound 18j) is an effective EGFR inhibitor with IC50 values of 23.6 and 307.5 nM for EGFRLR/TM/CS and EGFRWT, respectively. It has anti-proliferative activity and inhibits the phosphorylation of EGFR. EGFR-IN-70 can be used in cancer research.

     EGFR-IN-70 Chemical Structure
  101. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9 Chemical Structure

Items 301 to 400 of 1198 total

per page
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Set Descending Direction